Knowing stock market today at a glance

Pulmonx Corp (LUNG) Shares Soar 11.8% on Strong Q1 Earnings

Mover TrackerThursday, May 1, 2025 5:09 am ET

1min read

Pulmonx Corp (LUNG) shares surged 11.8% in pre-market trading on May 1, 2025, driven by strong first-quarter financial results.

Pulmonx reported a 20% increase in total revenue for the first quarter of 2025, reaching $22.5 million. This growth was fueled by a 39% increase in international revenue and an 11% increase in U.S. revenue. The company's marketing and peer-to-peer education efforts were highlighted as key contributors to this success.

CEO Steve Williamson emphasized that pulmonx achieved worldwide sales of $22.5 million in Q1 2025, representing a 20% growth year-over-year. This performance aligns with the company's projection of 20% long-term growth, driven by its expanded product offerings and strategic initiatives.

Pulmonx's strong Q1 performance has positioned the company for continued growth in 2025. The company's projected full-year revenue range of $96 million to $98 million reflects anticipated growth of 15% to 17% over 2024. This outlook, combined with the company's innovative treatments for severe emphysema, has bolstered investor confidence in Pulmonx's future prospects.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.